News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • Trump and Italy's Meloni publicly clashed over Italy's opposition to U.S. military action against Iran, increasing allied diplomatic tension.
  • Trump said the Lincoln Memorial reflecting pool may need partial draining for repairs after alleged vandalism.
  • Analysts warn the ECB's inflation-first stance raises the likelihood of further euro-zone rate hikes despite weak growth.
  • Analysts recommend buying Assa Abloy after price weakness, citing durable cash flow and a $105 target.
  • Trade calls: add Trane Technologies for HVAC and AI data-center exposure, and buy YETI as a mid-term long on brand strength.

Latest Articles

Park Ha Biological Technology Co., Ltd. announces strategic partnership with Star Plus Legend Group’s wholly-owned subsidiary to build an AI-powered skincare and health ecosystem and expand its healthcare reach

Park Ha Biological Technology Co., Ltd. announces strategic partnership with Star Plus Legend Group’s wholly-owned subsidiary to build an AI-powered skincare and health ecosystem and expand its healthcare reach

Park Ha Biological Technology Co., Ltd., listed on NASDAQ as BYAH, has formed a strategic partnership with Star Plus Action, a subsidiary of Hong Kong-listed Star Plus Legend Holdings. The collaboration aims to merge AI technology, skincare product development, celebrity IP management, and health maintenance to innovate the beauty and wellness indu…

OFA Group Receives Additional 180-Day Nasdaq Compliance Period; Nasdaq Confirms Company Remains Compliant with All Continued Listing Standards Other Than the Minimum Bid Price Requirement

OFA Group Receives Additional 180-Day Nasdaq Compliance Period; Nasdaq Confirms Company Remains Compliant with All Continued Listing Standards Other Than the Minimum Bid Price Requirement

OFA Group (Nasdaq: OFAL) announced that Nasdaq has granted it a second 180-day extension, until December 7, 2026, to regain compliance with the minimum $1.00 bid price per share rule. The company remains compliant with all other Nasdaq Capital Market listing standards. OFA may implement a reverse stock split if necessary to meet the requirement. Tr…

KE Holdings Inc. Announces Results of Annual General Meeting

KE Holdings Inc. Announces Results of Annual General Meeting

KE Holdings Inc. reported that all resolutions presented at its 2026 Annual General Meeting were approved, including amendments to its memorandum and articles of association, the re-election of key directors, and granting of general mandates for share issuance and repurchase. The company remains focused on its integrated online and offline real est…

Cogent Biosciences Announces Preclinical Data from Novel JAK2 V617F Inhibitor at the 2026 European Hematology Association (EHA) Congress

Cogent Biosciences Announces Preclinical Data from Novel JAK2 V617F Inhibitor at the 2026 European Hematology Association (EHA) Congress

Cogent Biosciences announced encouraging preclinical results of CGT1145, a novel JAK2 V617F mutant-selective inhibitor, at the 2026 European Hematology Association Congress. The drug showed over 100-fold selectivity for the mutant over wild-type JAK2, with potential to treat myeloproliferative neoplasms while minimizing off-target effects. The comp…

Cogent Biosciences Announces Detailed Data from APEX Pivotal Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis at the 2026 European Hematology Association (EHA) Congress

Cogent Biosciences Announces Detailed Data from APEX Pivotal Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis at the 2026 European Hematology Association (EHA) Congress

Cogent Biosciences reported detailed and updated clinical data from its pivotal APEX trial of bezuclastinib in patients with advanced systemic mastocytosis (AdvSM), demonstrating a high objective response rate, robust disease pathology improvements, and a favorable safety profile. The company plans an NDA submission in June 2026 and anticipates FDA…

Kalaris to Present at Clinical Trials at the Summit 2026

Kalaris to Present at Clinical Trials at the Summit 2026

Kalaris Therapeutics announced the presentation of Phase 1a clinical trial data for its lead asset TH103, a novel dual-targeting biologic for neovascular Age-Related Macular Degeneration (nAMD), at Clinical Trials at the Summit 2026. The data demonstrates early safety and efficacy signals. TH103, designed by noted VEGF scientist Dr. Napoleone Ferra…

UniFirst Shareholders Approve Transaction with Cintas

UniFirst Shareholders Approve Transaction with Cintas

UniFirst Corporation announced that more than 99% of shareholders approved its acquisition by Cintas Corporation. Under the agreement, UniFirst shareholders will receive $155 per share in cash plus 0.7720 shares of Cintas stock. The transaction is expected to close in the second half of 2026, pending customary conditions and regulatory approvals. T…

Profusa Submits Response Package to GMED as Part of Ongoing CE Mark Review Process for Lumee® Oxygen Platform

Profusa Submits Response Package to GMED as Part of Ongoing CE Mark Review Process for Lumee® Oxygen Platform

Profusa, Inc. announced the submission of its response to the European notified body GMED as part of the ongoing Medical Device Regulation (MDR) conformity assessment for its Lumee Oxygen Platform. This milestone advances the company's efforts to obtain CE Mark certification, critical for commercializing its real-time tissue oxygen monitoring biose…

Independent Bank Corporation Announces Regulatory Approvals to Acquire HCB Financial Corp. and Highpoint Community Bank

Independent Bank Corporation Announces Regulatory Approvals to Acquire HCB Financial Corp. and Highpoint Community Bank

Independent Bank Corporation (NASDAQ: IBCP) announced it has received regulatory approval from the Federal Reserve Bank of Chicago and the Michigan Department of Insurance and Financial Services to acquire HCB Financial Corp., the parent company of Highpoint Community Bank. The merger, pending HCB shareholder approval, is expected to close July 1, …

Rezolve Ai Board Moves to Authorize Capital Reduction and Up to $300 Million Share Repurchase Program

Rezolve Ai Board Moves to Authorize Capital Reduction and Up to $300 Million Share Repurchase Program

Rezolve Ai's Board of Directors will seek shareholder approval to reduce capital and repurchase up to $300 million of ordinary shares through an agreement with BTIG. The program demonstrates confidence in the company's growth prospects and aims to address what the Board sees as market undervaluation. The repurchases will be funded from cash reserve…

Hezbollah Says It Expects Lebanon to Be Included in Any U.S.-Iran Deal

Hezbollah Says It Expects Lebanon to Be Included in Any U.S.-Iran Deal

A senior Hezbollah politician said the group is confident Iran will demand that any agreement with the United States address the situation in Lebanon, as mediators report progress toward a possible memorandum. Despite talks and several U.S.-announced ceasefires, combat in southern Lebanon and new Israeli airstrikes were reported on Friday.

3 E Network CEO Outlines Strategic Vision for Robotics, Highlighting Silicon Innovation and Edge AI

3 E Network CEO Outlines Strategic Vision for Robotics, Highlighting Silicon Innovation and Edge AI

3 E Network Technology Group Limited, a Nasdaq-listed B2B IT business solutions provider, announced its strategic roadmap to become a next-generation AI infrastructure provider focusing on robotics. CEO Dr. Tingjun Yang emphasized advancing edge AI through silicon hardware innovation, hardware-software co-design, and building a scalable computing p…

Scilex Holding Company (“Scilex”) Confirms the Previously Announced Payment Date of June 15, 2026 for the Dividend of Semnur Pharmaceuticals, Inc. Common Stock to Holders of Scilex Common Stock and other Eligible Equity Securities

Scilex Holding Company (“Scilex”) Confirms the Previously Announced Payment Date of June 15, 2026 for the Dividend of Semnur Pharmaceuticals, Inc. Common Stock to Holders of Scilex Common Stock and other Eligible Equity Securities

Scilex Holding Company (Nasdaq: SCLX), a US-based biopharmaceutical company specializing in non-opioid pain management products, has confirmed the payment date of June 15, 2026, for a dividend of Semnur Pharmaceuticals, Inc. (OTC: SMNR) common stock to its shareholders. Eligible holders as of June 1, 2026, will receive one share of Semnur common st…